Summit Therapeutics PLC Company Profile (NASDAQ:SMMT)

About Summit Therapeutics PLC (NASDAQ:SMMT)

Summit Therapeutics PLC logoSummit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SMMT
  • CUSIP: N/A
  • Web: www.summitplc.com
Capitalization:
  • Market Cap: $157.24 million
  • Outstanding Shares: 12,381,000
Average Prices:
  • 50 Day Moving Avg: $12.81
  • 200 Day Moving Avg: $11.92
  • 52 Week Range: $5.31 - $19.75
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.10
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.26 million
  • Price / Sales: 29.89
  • Book Value: ($0.84) per share
  • Price / Book: -15.12
Profitability:
  • EBIDTA: ($31,670,000.00)
  • Net Margins: -507.08%
  • Return on Equity: -30,092.17%
  • Return on Assets: -66.82%
Debt:
  • Current Ratio: 2.59%
  • Quick Ratio: 2.58%
Misc:
  • Average Volume: 10,317 shs.
  • Beta: 0.38
  • Short Ratio: 2.2
 

Frequently Asked Questions for Summit Therapeutics PLC (NASDAQ:SMMT)

What is Summit Therapeutics PLC's stock symbol?

Summit Therapeutics PLC trades on the NASDAQ under the ticker symbol "SMMT."

When will Summit Therapeutics PLC make its next earnings announcement?

Summit Therapeutics PLC is scheduled to release their next quarterly earnings announcement on Thursday, September, 14th 2017. View Earnings Estimates for Summit Therapeutics PLC.

Where is Summit Therapeutics PLC's stock going? Where will Summit Therapeutics PLC's stock price be in 2017?

5 brokers have issued 1 year price objectives for Summit Therapeutics PLC's shares. Their predictions range from $24.00 to $30.00. On average, they expect Summit Therapeutics PLC's stock price to reach $27.40 in the next twelve months. View Analyst Ratings for Summit Therapeutics PLC.

Who are some of Summit Therapeutics PLC's key competitors?

Who are Summit Therapeutics PLC's key executives?

Summit Therapeutics PLC's management team includes the folowing people:

  • Glyn Edwards, Chief Executive Officer, Executive Director
  • Erik Ostrowski, Chief Financial Officer
  • David Roblin, Chief Operating Officer, President - Research and Development
  • Ralf H. Rosskamp M.D., Chief Medical Officer
  • Frank Murdoch Armstrong, Non-Executive Chairman of the Board
  • Valerie L. Andrews, Non-Executive Director
  • Stephen J. Davies, Non-Executive Director
  • Barry J. Price Ph.D., Non-Executive Director
  • David Wurzer CPA, Non-Executive Director

When did Summit Therapeutics PLC IPO?

(SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

Who owns Summit Therapeutics PLC stock?

Summit Therapeutics PLC's stock is owned by many different of retail and institutional investors. Top institutional investors include AXA (2.32%), First Eagle Investment Management LLC (1.41%), Sphera Funds Management LTD. (1.15%), Granite Point Capital Management L.P. (0.95%) and Acadian Asset Management LLC (0.10%). View Institutional Ownership Trends for Summit Therapeutics PLC.

Who sold Summit Therapeutics PLC stock? Who is selling Summit Therapeutics PLC stock?

Summit Therapeutics PLC's stock was sold by a variety of institutional investors in the last quarter, including AXA and Sphera Funds Management LTD.. View Insider Buying and Selling for Summit Therapeutics PLC.

Who bought Summit Therapeutics PLC stock? Who is buying Summit Therapeutics PLC stock?

Summit Therapeutics PLC's stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. View Insider Buying and Selling for Summit Therapeutics PLC.

How do I buy Summit Therapeutics PLC stock?

Shares of Summit Therapeutics PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Summit Therapeutics PLC's stock price today?

One share of Summit Therapeutics PLC stock can currently be purchased for approximately $12.70.


MarketBeat Community Rating for Summit Therapeutics PLC (NASDAQ SMMT)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  103 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  168
MarketBeat's community ratings are surveys of what our community members think about Summit Therapeutics PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Summit Therapeutics PLC (NASDAQ:SMMT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $27.40 (115.75% upside)

Analysts' Ratings History for Summit Therapeutics PLC (NASDAQ:SMMT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/22/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$24.00LowView Rating Details
6/16/2017Canaccord GenuityReiterated RatingBuy$28.00LowView Rating Details
11/16/2016Royal Bank Of CanadaBoost Price TargetOutperform$26.00 -> $29.00N/AView Rating Details
10/4/2016Needham & Company LLCBoost Price TargetBuy$22.00 -> $30.00N/AView Rating Details
9/16/2016HC WainwrightInitiated CoverageBuy$26.00N/AView Rating Details
6/21/2016Janney Montgomery ScottInitiated CoverageBuyN/AView Rating Details
(Data available from 8/23/2015 forward)

Earnings

Earnings History for Summit Therapeutics PLC (NASDAQ:SMMT)
Earnings by Quarter for Summit Therapeutics PLC (NASDAQ:SMMT)
Earnings History by Quarter for Summit Therapeutics PLC (NASDAQ SMMT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/14/2017        
8/27/2015Q215($0.06)($0.55)$0.39 million$0.67 millionViewListenView Earnings Details
6/11/2015Q115($0.06)($0.45)$0.39 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Summit Therapeutics PLC (NASDAQ:SMMT)
2017 EPS Consensus Estimate: ($1.92)
2018 EPS Consensus Estimate: ($0.98)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.78)($0.78)($0.78)
Q3 20171($0.64)($0.64)($0.64)
Q4 20171($0.50)($0.50)($0.50)
Q1 20181($0.65)($0.65)($0.65)
Q2 20181$1.15$1.15$1.15
Q3 20181($0.71)($0.71)($0.71)
Q4 20181($0.77)($0.77)($0.77)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Summit Therapeutics PLC (NASDAQ:SMMT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Summit Therapeutics PLC (NASDAQ:SMMT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Summit Therapeutics PLC (NASDAQ:SMMT)
Latest Headlines for Summit Therapeutics PLC (NASDAQ:SMMT)
Source:
DateHeadline
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Expected to Announce Quarterly Sales of $31.37 Million
www.americanbankingnews.com - August 9 at 7:20 AM
americanbankingnews.com logoSummit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - August 8 at 11:04 AM
americanbankingnews.com logoSummit Therapeutics PLC (NASDAQ:SMMT) Expected to Post Earnings of $1.38 Per Share
www.americanbankingnews.com - August 7 at 6:28 PM
globenewswire.com logoSummit Therapeutics plc : Total voting rights - GlobeNewswire (press release)
globenewswire.com - August 1 at 6:22 AM
finance.yahoo.com logoSarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View
finance.yahoo.com - July 21 at 7:10 AM
americanbankingnews.com logo Analysts Expect Summit Therapeutics PLC (NASDAQ:SMMT) Will Post Quarterly Sales of $31.37 Million
www.americanbankingnews.com - July 20 at 11:54 AM
globenewswire.com logoSummit Therapeutics plc : Grant of Share Options and Restricted Stock Units
globenewswire.com - July 20 at 7:50 AM
americanbankingnews.com logo Analysts Expect Summit Therapeutics PLC (NASDAQ:SMMT) to Post $1.38 Earnings Per Share
www.americanbankingnews.com - July 18 at 2:43 PM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 14 at 11:19 AM
finance.yahoo.com logoCorporate News Blog - Norgine’s Acquisition of Merus Labs Crosses Final Hurdle as Spanish Anti-Trust Agency Okays the Deal
finance.yahoo.com - July 6 at 9:36 AM
americanbankingnews.com logoSummit Therapeutics PLC (NASDAQ:SMMT) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - July 4 at 8:17 AM
finance.yahoo.com logoCan Summit Therapeutics (SMMT) Run Higher on Strong Earnings Estimate Revisions?
finance.yahoo.com - July 4 at 7:25 AM
nasdaq.com logoSarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017 - Nasdaq
www.nasdaq.com - July 1 at 7:35 AM
globenewswire.com logoSummit Therapeutics plc : Exercise of Share Options Nasdaq:SMMT - GlobeNewswire (press release)
globenewswire.com - June 28 at 8:05 AM
americanbankingnews.com logoBrokers Set Expectations for Summit Therapeutics PLC's Q2 2018 Earnings (SMMT)
www.americanbankingnews.com - June 26 at 7:51 AM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) PT Set at $24.00 by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - June 24 at 11:56 AM
finance.yahoo.com logoSummit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress
finance.yahoo.com - June 22 at 1:38 PM
finance.yahoo.com logoSummit Therapeutics Plc :SMMT-US: Earnings Analysis: Q1, 2018 By the Numbers : June 22, 2017
finance.yahoo.com - June 22 at 1:38 PM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - June 19 at 11:24 AM
americanbankingnews.com logoCanaccord Genuity Reiterates Buy Rating for Summit Therapeutics PLC (SMMT)
www.americanbankingnews.com - June 16 at 4:58 PM
globenewswire.com logoSummit Therapeutics to Participate in JMP Securities Life Sciences Conference - GlobeNewswire (press release)
globenewswire.com - June 15 at 3:17 PM
finance.yahoo.com logoSummit Therapeutics to Participate in JMP Securities Life Sciences Conference
finance.yahoo.com - June 15 at 3:17 PM
globenewswire.com logoSummit Therapeutics Reports Financial Results for the First Quarter ... - GlobeNewswire (press release)
globenewswire.com - June 15 at 5:42 AM
globenewswire.com logoSummit Therapeutics plc : 1st Quarter Results - GlobeNewswire (press release)
globenewswire.com - June 14 at 8:03 AM
finance.yahoo.com logoSummit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational Progress
finance.yahoo.com - June 14 at 8:03 AM
finance.yahoo.com logoSummit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2017 on 14 June 2017
finance.yahoo.com - June 13 at 9:51 AM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - June 6 at 7:23 PM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 23 at 10:30 AM
americanbankingnews.com logoShort Interest in Summit Therapeutics PLC (SMMT) Declines By 3.7%
www.americanbankingnews.com - May 8 at 7:27 AM
americanbankingnews.com logoSummit Therapeutics PLC Expected to Earn Q1 2018 Earnings of ($0.65) Per Share (SMMT)
www.americanbankingnews.com - May 4 at 5:46 PM
americanbankingnews.com logoBrokerages Set Summit Therapeutics PLC (SMMT) Price Target at $28.25
www.americanbankingnews.com - May 4 at 1:04 AM
globenewswire.com logoSummit Therapeutics plc: Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases - GlobeNewswire (press release)
globenewswire.com - May 2 at 9:25 AM
finance.yahoo.com logoPhase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole …
finance.yahoo.com - April 28 at 9:06 PM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Receiving Somewhat Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 28 at 5:16 PM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 28 at 12:24 PM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Given News Impact Rating of 0.30
www.americanbankingnews.com - April 23 at 8:09 PM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Receives Daily Coverage Optimism Rating of 0.31
www.americanbankingnews.com - April 17 at 6:13 PM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Receiving Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 13 at 5:03 PM
globenewswire.com logoSummit Therapeutics plc : Grant of Share Options - GlobeNewswire (press release)
globenewswire.com - April 12 at 11:05 PM
globenewswire.com logoSummit Therapeutics plc : Exercise of Options - GlobeNewswire (press release)
www.globenewswire.com - April 11 at 7:38 PM
finance.yahoo.com logoSummit Therapeutics Plc :SMMT-US: Earnings Analysis: Q4, 2017 By the Numbers : April 4, 2017
finance.yahoo.com - April 7 at 12:38 PM
americanbankingnews.com logoSummit Therapeutics PLC (SMMT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 3 at 1:42 PM
globenewswire.com logoSummit Therapeutics File US Annual Report on Form 20-F - GlobeNewswire (press release)
globenewswire.com - April 2 at 7:42 PM
seekingalpha.com logoSummit Therapeutics' (SMMT) CEO Glyn Edwards on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 29 at 11:57 PM
streetinsider.com logoSummit (SMMT) to Proceed with Planned Extension of Ongoing ... - StreetInsider.com
www.streetinsider.com - March 27 at 7:05 PM
globenewswire.com logoSummit Therapeutics plc : Notice of Results - GlobeNewswire (press release)
globenewswire.com - March 27 at 7:05 PM
finance.yahoo.com logoSummit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017
finance.yahoo.com - March 27 at 9:09 AM
finance.yahoo.com logo7:01 am Summit Therapeutics to proceed with the planned extension phase of PhaseOut DMD
finance.yahoo.com - March 27 at 9:09 AM
americanbankingnews.com logoSummit Therapeutics PLC's (SMMT) "Buy" Rating Reiterated at Oppenheimer Holdings Inc.
www.americanbankingnews.com - March 25 at 12:58 AM
finance.yahoo.com logoAmgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop - Yahoo Finance
finance.yahoo.com - March 22 at 8:21 AM

Social

Chart

Summit Therapeutics PLC (SMMT) Chart for Wednesday, August, 23, 2017

This page was last updated on 8/23/2017 by MarketBeat.com Staff